OpenLB
Open Library of Bioscience

Aptamers as new promising entities for therapeutics: our experience from the neurological diseases.

Abstract

No abstract text available.

References

1. Aliena-Valero A, Hern��ndez-Jim��nez M, L��pez-Morales MA, Tamayo-Torres E, Castell��-Ruiz M, Pi��eiro D, Rib�� M, Salom JB (2024) Cerebroprotective effects of the TLR4-binding DNA aptamer ApTOLL in a rat model of ischemic stroke and thrombectomy recanalization. Pharmaceutics 16:741.
2. Ben��tez-Fern��ndez R, Josa-Prado F, S��nchez E, Lao Y, Garc��a-Rubia A, Cumella J, Mart��nez A, Palomo V, de Castro F (2024) Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis. CNS Neurosci Ther 30:e14552.
3. Bierhansl L, Hartung HP, Aktas O, Ruck T, Roden M, Meuth SG (2022) Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov 21:578���600.
4. Fern��ndez G, Moraga A, Cuartero MI, Garc��a-Culebras A, Pe��a-Mart��nez C, Pradillo JM, Hern��ndez-Jim��nez M, Sacrist��n S, Ayuso MI, Gonzalo-Gobernado R, Fern��ndez-L��pez D, Mart��n ME, Moro MA, Gonz��lez VM, Lizasoain I (2018) TLR4-binding DNA aptamers show a protective effect against acute stroke in animal models. Mol Ther 26:2047���2059.
5. Fern��ndez-G��mez B, Marchena MA, Pi��eiro D, G��mez-Mart��n P, S��nchez E, La�� Y, Valencia G, Nocera S, Ben��tez-Fern��ndez R, Casta��o-Le��n AM, Lagares A, Hern��ndez-Jim��nez M, de Castro F (2024) ApTOLL: a new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis. Br J Pharmacol 181:3263���3281.
6. Hern��ndez-Jim��nez M, Mart��n-V��lchez S, Ochoa D, Mej��a-Abril G, Rom��n M, Camargo-Mamani P, Luquero-Bueno S, Jilma B, Moro MA, Fern��ndez G, Pi��eiro D, Rib�� M, Gonz��lez VM, Lizasoain I, Abad-Santos F (2022) First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. Mol Ther Nucleic Acids 28:124���135.
7. Hern��ndez-Jim��nez M, et al. (2023) Safety and efficacy of ApTOLL in patients with ischemic stroke undergoing endovascular treatment: a phase 1/2 randomized clinical trial. JAMA Neurol 80:779���788.
8. Kong AH, Wu AJ, Ho OK, Leung MM, Huang AS, Yu Y, Zhang G, Lyu A, Li M, Cheung KH (2023) Exploring the potential of aptamers in targeting neuroinflammation and neurodegenerative disorders: opportunities and challenges. Int J Mol Sci 24:11780.
9. Kovacevic KD, Gilbert JC, Jilma B (2018) Pharmacokinetics, pharmacodynamics and safety of aptamers. Adv Drug Deliv Rev 134:36���50.
10. Medina-Rodr��guez EM, Arenzana FJ, Pastor J, Redondo M, Palomo V, Garc��a de Sola R, Gil C, Mart��nez A, Bribi��n A, de Castro F (2013) Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell Mol Life Sci 70:3449���3462.
11. Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ 3rd, Wootla B, Kunbaz A, Rodriguez M (2018) A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next? Expert Opin Biol Ther 18:545���560.
12. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505���510.